Neoadjuvant Breast Cancer Trials: Translational Research in Drug Development

被引：0

作者：

Beaver J.A. ^{[1
]}

Amiri-Kordestani L. ^{[1
]}

Philip R. ^{[2
]}

Cortazar P. ^{[1
]}

机构：

[1] Center for Drug Evaluation and Research, US Food and Drug Administration, White Oak, MD

[2] Center for Devices and Radiological Health, US Food and Drug Administration, White Oak, MD

来源：

Current Breast Cancer Reports | 2015年 / 7卷 / 3期

关键词：

Assessment; Biomarkers; Clinical trials; Drug development; Drug efficacy; Neoadjuvant trials;

D O I：

10.1007/s12609-015-0183-2

中图分类号：

学科分类号：

摘要：

In addition to reducing the size and extent of locally advanced breast cancer tumors, neoadjuvant trials allow for rapid assessment of drug efficacy and could expedite development and approval of treatments for early breast cancer. For these reasons, clinical trials in the neoadjuvant setting are prime opportunities to study translational science, pathologic response, genetic biomarkers, and imaging biomarkers. In this review, we provide a summary of the efforts to identify biomarkers aimed to understand tumor biology and to prognosticate and predict response to neoadjuvant therapy for early breast cancer. We also provide a perspective on how neoadjuvant trials can be used to pursue translational research and drug development. © 2015, Springer Science+Business Media New York (outside the USA).

引用

页码：151 / 160

页数：9

共 50 条

[1] The Neoadjuvant Model as a Translational Tool for Drug and Biomarker Development in Breast Cancer
Spring, Laura
[J]. ONCOLOGIST, 2018, 23 : S4 - S4
[2] Translational research in neoadjuvant breast cancer studies
von Minckwitz, G.
[J]. GEBURTSHILFE UND FRAUENHEILKUNDE, 2006, 66 (09) : 827 - 832
[3] Neoadjuvant Therapy for Breast Cancer as a Model for Translational Research
Selli, Cigdem
Sims, Andrew H.
[J]. BREAST CANCER-BASIC AND CLINICAL RESEARCH, 2019, 13
[4] Neoadjuvant Trials in ER+ Breast Cancer: A Tool for Acceleration of Drug Development and Discovery
Guerrero-Zotano, Angel L.
Arteaga, Carlos L.
[J]. CANCER DISCOVERY, 2017, 7 (06) : 561 - 574
[5] Neoadjuvant Breast Cancer Therapy and Drug Development
Cortazar, Patricia
Kluetz, Paul G.
[J]. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2015, 13 (11) : 755 - 761
[6] Strategies to incorporate translational research science into clinical trials in breast cancer
Fumagalli D.
Desmedt C.
Piccart M.
Sotiriou C.
[J]. Current Breast Cancer Reports, 2010, 2 (4) : 208 - 213
[7] Breast Cancer Trials biobank: Clinically annotated specimens for translational research
Zdenkowski, Nicholas
Badger, Heath
[J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2021, 17 : 22 - 23
[8] TRANSLATIONAL RESEARCH AND DRUG DEVELOPMENT
Benavides, J.
[J]. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2011, 109 : 2 - 2
[9] The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer
DeMichele, Angela
Yee, Douglas
Berry, Donald A.
Albain, Kathy S.
Benz, Christopher C.
Boughey, Judy
Buxton, Meredith
Chia, Stephen K.
Chien, Amy J.
Chui, Stephen Y.
Clark, Amy
Edmiston, Kirsten
Elias, Anthony D.
Forero-Torres, Andres
Haddad, Tufia C.
Haley, Barbara
Haluska, Paul
Hylton, Nola M.
Isaacs, Claudine
Kaplan, Henry
Korde, Larissa
Leyland-Jones, Brian
Liu, Minetta C.
Melisko, Michelle
Minton, Susan E.
Moulder, Stacy L.
Nanda, Rita
Olopade, Olufunmilayo I.
Paoloni, Melissa
Park, John W.
Parker, Barbara A.
Perlmutter, Jane
Petricoin, Emanuel F.
Rugo, Hope
Symmans, Fraser
Tripathy, Debasish
Veer, Laura J. Van't
Viscusi, Rebecca K.
Wallace, Anne
Wolf, Denise
Yau, Christina
Esserman, Laura J.
[J]. CLINICAL CANCER RESEARCH, 2015, 21 (13) : 2911 - 2915
[10] Neoadjuvant as Future for Drug Development in Breast Cancer-Response
DeMichele, Angela
Yee, Douglas
Paoloni, Melissa
Berry, Don
Esserman, Laura J.
[J]. CLINICAL CANCER RESEARCH, 2016, 22 (01) : 269 - 269

← 1 2 3 4 5 →